@article {3598,
	title = {Complete remission of VZV reactivation treated with valganciclovir in a patient with total lymphocyte depletion and acute kidney injury after allogeneic bone marrow transplantation.},
	journal = {APMIS},
	volume = {123},
	year = {2015},
	month = {2015 Jan},
	pages = {77-80},
	abstract = {<p>Varicella zoster virus (VZV), a threat for hematopoietic stem cell transplantation (HSCT) recipients, is still one of the most common viral pathogens that affect these patients with a reported incidence ranging between 17\% and 50\% in the post transplantation period. Valganciclovir (V-GCV), a valine ester pro-drug of GCV orally administrable, has recently shown great activity against CMV infections, but there are no reports of its clinical efficacy against VZV. We here report a case history of a patient with positive serologic test for VZV, who underwent allogeneic HSCT and developed an atypical varicella-like illness. First-line therapy with foscarnet had to be discontinued due rapid development of renal impairment (creatinine: 2.60 mg/dL, urea: 130.6 mg/dL) and therefore was switched to V-GCV. The renal impairment and skin lesions of the patient fully recovered after few days of therapy, even though the patient had complete lymphocyte depletion. This is the first case of a patient with chickenpox-like illness treated successfully with V-GCV.</p>},
	keywords = {Acute Kidney Injury, Adolescent, Bone Marrow Transplantation, Fatal Outcome, Female, Ganciclovir, Herpes Zoster, Herpesvirus 3, Human, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Viral Load},
	issn = {1600-0463},
	doi = {10.1111/apm.12303},
	author = {Maximova, Natalia and Antonio, Pizzol and Marilena, Granzotto and Rovere, Francesca and Tamaro, Paolo}
}
